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Abstract: Endometriosis is one of the most common benign gynecological disorders, affecting 
almost 10%–15% of all women of reproductive age and .30% of infertile women. The pathology 
is associated with various distressing symptoms, particularly pelvic pain, which adversely affect 
patients’ quality of life. It is an estrogen-dependent disease. There is evidence both in animals 
and in humans that metal ions can activate the estrogen receptors. They are defined as a variety 
of xenoestrogens, called metalloestrogens, which could act as endocrine disruptors. Therefore, it 
could be considered to act on this gynecological disorder using food supplements containing trace 
elements (ie, nutripuncture). The assumption is that they could modulate estrogen receptors and 
thus influence the tropism and the survival of cells involved in endometriosis. By a modulation 
of the antioxidant system, they might also interact with various parameters influencing tissue 
biochemistry. The objective of this article is to describe and discuss the design and methodology 
of an ongoing double-blind, randomized, placebo-controlled study aiming to evaluate the efficacy 
of metal trace elements on the reduction of pain and improvement of quality of life, in patients 
with a revised American Fertility Society Score Stages II–IV endometriosis, combined or not with 
adenomyosis, during a treatment period of 4 months. Trace elements or placebo is proposed in 
the absence of any other treatment or as an add-on to current therapies, such as sexual hormones, 
nonsteroidal anti-inflammatory drugs, and surgery. A placebo run-in period of one menstrual 
cycle or 30 days for women in amenorrhea has been scheduled to eliminate the patients who are 
responding too much to the placebo. After a 1:1 ratio randomization on Day 0, the treatment with 
trace elements or placebo will last for 4 months (120 days).
Keywords: endometriosis, trace elements, randomized, placebo-controlled study, pain, quality 
of life
Introduction
Endometriosis is defined as the presence of endometrial tissue, including both glandular 
epithelium and stroma, outside the uterine cavity. If the prevalence of endometriosis in 
specific categories of patients has been reported, the real prevalence in the general popu-
lation is not known1 but is one of the most common benign gynecological disorders, 
affecting almost 10%–15% of all women of reproductive age and .30% of infertile 
women.2,3 It is associated with various distressing symptoms, such as dysmenorrhea, 
dyspareunia, pelvic pain, and subfertility, which adversely affect patients’ quality 
of life (QoL). A growing body of evidence suggests that a combination of genetic, 
hormonal, environmental, immunological, and anatomical factors plays a role in the 
pathogenesis of this disorder.4–6
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There is a general agreement that if ablative surgery by 
laparoscopy is the treatment of choice for peritoneal lesions, 
conservative laparoscopic surgery is the treatment of choice 
for ovarian endometriotic cysts7,8 because medical treatment 
alone is insufficient.9 However, a frustrating aspect of lap-
aroscopic excision is cyst recurrence after surgery, with a 
cumulative rate of endometrioma recurrence after 2–5 years 
of follow-up of 12%–30%.10
A recent overview has focused on 17 published Cochrane 
systematic reviews concerning the interventions for pain relief 
and for subfertility in premenopausal women with clinically 
diagnosed endometriosis. Suppression of menstrual cycles 
with gonadotrophin-releasing hormone (GnRH) analogs, the 
levonorgestrel-releasing intrauterine system, and danazol were 
beneficial interventions. Laparoscopic treatment of endo-
metriosis and excision of endometrioma were also associated 
with improvements in pain. The evidence on nonsteroidal 
anti-inflammatory drugs was inconclusive. In women with 
endometriosis undergoing assisted reproduction, 3 months 
of treatment with GnRH agonist improved pregnancy rates. 
Excisional surgery improved spontaneous pregnancy rates 
within 9–12 months after surgery compared to ablative sur-
gery. Laparoscopic surgery improved live birth and pregnancy 
rates compared to diagnostic laparoscopy alone. There was no 
evidence that medical treatment improved clinical pregnancy 
rates. Evidence on harms was scanty, but GnRH analogs, 
danazol, and depot progestagens were associated with higher 
rates than other interventions.11
Endometriosis is an estrogen-dependent disease. There is 
evidence both in animals and in humans that metal ions can 
activate the estrogen receptors. They are defined as a variety 
of xenoestrogens, called metalloestrogens,12–14 which could 
act as endocrine disruptors.6
Antioxidants could confer a certain protection against the 
endometriosis lesions, and trace elements could modify the 
oxidative stress levels with an impact on endometriosis.15–18
The effects of major trace elements on endometriosis have 
been summarized in Table 1. They can have positive, negative, 
and/or mitigated effects on the disease or on the conditions 
leading to it. However, the situation is not so clear, and the vast 
Table 1 Summary of the effects of the major trace elements (in alphabetical order) on endometriosis or on the potential conditions 
leading to the disease
Trace  
element
Short description of the  
positive effects
Short description of the negative  
effects
Short description of the mitigated 
effects
Boron No data available
Cadmium Clinical study: women suffering from 
endometriosis presented cadmium 
urine levels lower than the control 
women26
In vitro: cadmium can induce the 
proliferation of stromal cells derived from 
the eutopic endometrium of women with 
endometriosis27
Clinical study: data does not support 
a role for cadmium in the onset or 
the growth of endometriosis or deep 
endometriotic (adenomyotic) nodules28,29
No data available No data available Case–control study: no association 
between urinary cadmium 
concentrations and the risk of 
endometriosis30
Calcium No data available Animal model: upregulation of calcium 
channel in the spinal cord may contribute 
to pelvic organ cross-sensitization in painful 
endometriosis31
Clinical study: no evidence of differences 
in serum calcium concentrations 
between women suffering from 
endometriosis and control women32
No data available Ex vivo study: calcium-binding proteins 
seem to be increased in endometriosis-
associated nerve fibers and might play a role 
in the chronic inflammatory condition and 
the pain pathogenesis of endometriosis33
No data available
Chloride No data available No data available No data available
Chrome No data available No data available No data available
Copper No data available Clinical study: positive correlations were 
found between copper and total oxidant 
status and copper and oxidative stress 
index. Copper appears to be associated 
with the pathogenesis of and oxidative 
stress in endometriosis34
Ex vivo study: the expression of copper 
superoxide dismutase in endometriosis 
was persistently higher than the control 
levels throughout the menstrual cycle35
Fluorine No data available No data available No data available
Iodine No data available No data available No data available
(Continued)
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Table 1 (Continued)
Trace  
element
Short description of the  
positive effects
Short description of the negative  
effects
Short description of the mitigated 
effects
Iron No data available Ex vivo study: presence of iron-related 
compounds that are potentially toxic to the 
development of ovarian follicles adjacent 
to the endometrioma during in vitro 
fertilization36
Ex vivo study: ectopic endometrial 
stromal cells play a protective role for 
cancer-target epithelial cells by collecting 
excess iron37
No data available Ex vivo study: results suggest that iron 
overload induces a proendometriotic 
phenotype on healthy human endometrial 
stromal cells, which could participate in the 
endometriosis pathogenesis38
Clinical study: iron may diffuse from 
ovarian endometriomas into the 
adjacent ovarian tissue. However, 
this phenomenon does not appear to 
markedly affect ovarian function39
No data available Clinical study: disrupted iron homeostasis 
in the peritoneal cavity of women 
with endometriosis plays a role in the 
pathogenesis of the disease40
Review: accumulated data suggest that 
disrupted iron metabolism may induce 
oxidative stress in the peritoneal cavity 
of endometriosis patients41
No data available No data available Review: iron has a significant impact on 
endometriotic-cell gene expression42
Lead Clinical study: women suffering from 
endometriosis presented lead urine 
levels lower than control women26
No data available No data available
Magnesium No data available No data available No data available
Manganese No data available No data available Ex vivo study: the expression of 
manganese superoxide dismutase in 
endometriosis was persistently higher 
than the control levels throughout the 
menstrual cycle35
Molybdenum No data available No data available No data available
Nickel No data available Clinical study: blood samples from women 
suffering from endometriosis contained 
three times higher levels of nickel than 
the healthy control group. The estrogenic 
potential of nickel has been found to be 
similar to that of estradiol43
No data available
Phosphorus No data available Clinical study: the abnormal metabolism of 
phosphorus and the higher levels of serum 
P may play a role in the pathogenesis of 
endometriosis32
No data available
Potassium No data available No data available No data available
Selenium No data available No data available No data available
Silicon No data available No data available No data available
Sodium No data available No data available No data available
Zinc Clinical study: serum zinc levels 
in women with endometriosis 
are decreased, and this seems 
to actually confirm that this 
microelement can possibly affect the 
multifactorial pathogenesis of the 
disease44
No data available Clinical study: intrafollicular zinc 
levels were higher in women with 
endometriosis who subsequently 
became pregnant following in vitro 
fertilization45
majority of results have been obtained in vitro in animal mod-
els or ex vivo in tissues of patients suffering from the disease 
versus case–control. Without randomized, placebo-controlled 
trials, it is currently very difficult to conclude any clinically and 
statistically significant benefit for these trace elements.
Even though trace elements could potentially be interest-
ing, some of them are not authorized in food supplements 
(Official Journal of the European Union).19 This is the case 
for some heavy metals such as cadmium, nickel, or lead.
Taking into account these studies, it could perhaps be 
considered to act on this gynecological disorder with food 
supplements containing trace elements (ie, nutripuncture). 
The assumption is that they could modulate estrogen 
receptors and thus influence the tropism and the survival 
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of cells involved in endometriosis. By a modulation of the 
antioxidant system, they might also interact with various 
parameters influencing tissue biochemistry.
The company Pronutri (Carros, France) has developed 
an original formulation of eight different trace elements 
(authorized in food supplements by the European Union). It 
was initially tested in patients with problems of visual acu-
ity, and the doctors discovered that women suffering from 
visual problems and also endometriosis benefited from an 
improvement of their health status. Therefore, the laboratory 
decided to conduct a first preliminary empiric and observa-
tional study in ten women suffering from a revised American 
Fertility Society Score (AFSr) Stages I–IV endometriosis, 
which has revealed positive effects in all women, within 
60 days of treatment, in terms of regression of the disease and 
attenuation of symptoms, especially pelvic pain.
However, this was only indicative of a potential thera-
peutic effect, and the evidence was not of sufficient quality 
to recommend the treatment.
Therefore, the objective of this double-blind, ran-
domized, placebo-controlled study (ClinicalTrials.gov 
NCT02437175) is to evaluate the efficacy of this combi-
nation of metal trace elements on the reduction of pain, in 
patients with an AFSr Stages II–IV endometriosis, com-
bined or not to an adenomyosis, during a treatment period 
of 4 months.
Patients and methods
Study design
The design of the trial can be found in Figure 1. This is a pro-
spective, interventional, randomized (two parallel groups), 
double-blind, placebo-controlled study. It will be conducted 
in 12 centers distributed in France and Belgium.
This study will be conducted in accordance with the 
guidelines of Good Clinical Practice and International 
Conference on Harmonization and the last version of the 
Declaration of Helsinki.
It has already been submitted and approved by all central 
and peripheral ethics committees of France and Belgium, and 
the first patient was included on May 28, 2015.
Trace elements or placebo are proposed in the absence of 
any other treatment or as an add-on to current therapies, such 
as sexual hormones, nonsteroidal anti-inflammatory drugs, 
and surgery. At visit 1, patients must be either untreated or 
with the same treatments as mentioned above for a minimum 
of 2 months. A placebo run-in period of one menstrual cycle 
or 30 days for women in amenorrhea has been scheduled 
to eliminate the high placebo responders. After a 1:1 ratio 
randomization on Day 0, the treatment with trace elements 
or placebo will last for 4 months (120 days). Four medical 
visits (Days −45 to −30, 0, 60, and 120) and two phone 
contacts or direct contacts (Days 30 and 90) will be set up, 
ideally between the seventh and the 21st days of the menstrual 
cycle, if present.
Study procedures
The activities conducted at each visit, or contact, are 
described in Table 2.
The 30-item Endometriosis Health Profile (EHP-30)20–22 
QoL questionnaire will be completed by the patient on Days 
0, 60, and 120. During the entire study period, the patients 
will be asked to fill in a diary card in which they will record 
their pain (using a 100 mm Visual Analog Scale [VAS]), 
blood loss, NSAID (ibuprofen considered as the rescue 
medication, with a maximum dosage of 3× 600 mg/d) or 
other drugs consumption, and adverse events (AEs) (serious 
or nonserious). Phone or direct intermediate contacts will 
be used to reinforce the compliance and to record potential 
AEs (serious or nonserious). A urinary pregnancy test will 
be done at each visit.
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Table 2 Study procedures
Activity Visit 1 
Day −45/−30
Visit 2 
Day 0
PC/DC 
Day 30
Visit 3 
Day 60
PC/DC 
Day 90
Visit 4 
Day 120
Informed consent ●
Inclusion/exclusion criteria ● ●
Demography ●
Medical history ●
Physical examination ● ● ● ●
Urinary pregnancy test ● ● ● ●
Pain Visual Analog Scale (100 mm) ● ○ ○ ○ ○ ○
Endometriosis Health Profile-30 ● ● ●
Blood loss ○ ○ ○ ○ ○
Ibuprofen (rescue medication) ● ○ ○ ○ ○ ○
Other concomitant drugs ● ○ ○ ○ ○ ○
Randomization (1:1) ●
Nonserious and serious adverse events ● ○ ○ ○ ●
Diary cards distribution ● ● ●
Diary cards retrieval ● ● ●
Study drug distribution ● ● ●
Study drug retrieval ● ● ●
Compliance (reinforcement and calculation) ● ○ ● ○ ●
Study conclusion ●
Notes: ●, activity under the responsibility of the investigator; ○, information collected via the patient’s diary card.
Abbreviation: PC/DC, phone contact or direct contact.
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Eligibility criteria
Nonmenopausal woman (aged 18–45 years) consulting 
for pain related to an endometriosis (AFSr Stages II–IV), 
combined or not with an adenomyosis, previously confirmed 
by laparoscopy and/or laparotomy in the inclusion center, 
or obligatory by a biopsy (with or without MRI) in case 
the patient had not been followed in the center, treated or 
untreated, with sexual hormones, contraceptives or not (stable 
treatment for at least 2 months), or any other stabilized treat-
ment will be included after giving their written informed 
consent. The time between surgery and inclusion will be 
at least 6 months. The pain measured on VAS at inclusion 
(Days −45 to −30) will be at least 40 mm, and it cannot 
decrease by .20% during the run-in placebo period.
Women with a Stage I endometriosis, with an adenomyosis 
without endometriosis, pregnant, or presenting with another 
pathology, which could interfere with endometriosis and/or 
adenomyosis, or the study follow-up will be excluded.
During the course of the study, surgery, any major thera-
peutic change, and confirmed pregnancy will constitute the 
elimination criteria.
Study drug
During the run-in period, patients will take a sequence of 
ten oral tablets (to crush in order to facilitate the sublingual 
absorption) in the order 1–10, outside meal in the morning 
and in the evening.
After randomization, patients in the active treatment 
group will take Nutri Endo 1 (a sequence of ten oral tablets 
to crush in the order 1–10, outside meal in the morning) 
and Nutri Endo 2 (a sequence of ten oral tablets to crush in 
the order 1–10, outside meal in the evening) for 120 days 
(Laboratoires Pronutri, Carros, France) (Table 3). Patients 
in the placebo group will follow the same schedule with 
placebo tablets replacing Nutri Endo 1 and 2.
Objectives and endpoints
The primary objective of the study will be to assess the 
efficacy of metal trace elements versus placebo on the reduc-
tion of pain. The secondary objectives will be to evaluate 
the efficacy of metal trace elements versus placebo on the 
improvement of the QoL and on the decrease of the rescue 
medication consumption. The safety of metal trace elements 
versus placebo will also be assessed through the recording 
of potential nonserious (AEs) and serious adverse events 
(SAEs) during the entire study period.
The primary endpoint will be the change in the area under 
the curve (AUC) of pain, as determined by VAS, between the 
run-in placebo period and the 120-day treatment period in 
the two treatment groups.
The secondary endpoints will be the change in the total 
score of the EHP-30 QoL questionnaire between Day 60 or 
120 and Day 0, the number of ibuprofen tablets consumed 
during the 120-day treatment phase, and the frequency of 
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AEs and SAEs (considered related or not to the treatment) 
in the two treatment groups.
A confirmed pregnancy during the study will be an elimi-
nation criterion. The reason is not linked to any potential risk 
of the study drug on the pregnancy outcomes but to the fact 
that pregnancy can modify pain and therefore constitutes a 
significant pain measurement bias. For these reasons, preg-
nancy will not be considered as an AE but as a potentially 
positive outcome if the patient wanted to be pregnant. After 
elimination from the study, the patient will be followed-up 
by her gynecologist until delivery as usual.
Sample size justification
A sample size of 23 completed patients per group will have 
90% power to detect a difference in the percentage change in 
pain AUC of 20% between trace elements and placebo (based 
on a decrease of 10% in the placebo group, a decrease of 30% 
in the trace elements group, and a common standard devia-
tion of 20%), using an independent Student’s t-test with an 
alpha risk of 5%. Taking into account the pilot characteristic 
of the study, the absence of preliminary data and a drop-out 
rate after the run-in period of 15%–20%, 60 patients will be 
enrolled in order to complete 50 patients (25 trace elements 
and 25 placebo). Any drop-out patient will be replaced until 
the number of 50 completed patients has been reached.
Statistical analyses
The intention-to-treat cohort will be the primary population 
for the evaluation of efficacy and safety. It will include all 
randomized patients who will have taken at least one dose of 
treatment and for whom at least one result concerning efficacy 
or safety has been recorded after randomization.
The secondary population will be the per protocol cohort. 
It will include all patients having completed the study with-
out any major deviation from the protocol and in whom the 
global compliance (determined by counting the remaining 
treatment tablets) is at least 80%.
A paper case report form will be used to collect the data. 
After double data entry and resolution of all queries, the 
data will be migrated into the software IBM-SPSS Statistics 
Version 21.0 for statistical analyses. Missing values will 
not be replaced. The last observation carried forward will 
be determined for all parameters in noncompleted patients. 
Descriptive statistics will be used to characterize the patients 
at baseline. Student’s t-test (for continuous variables) and 
chi-square test, Fisher’s exact test, or Mann–Whitney test 
(for discrete variables) will be used to compare the two 
treatment groups at baseline. The primary and secondary 
efficacy endpoints will be compared between the two treat-
ment groups using the independent Student’s t-test. When 
more than two time points are considered to compare the two 
groups, analyses of variance for repeated measures, with the 
factor “time,” “treatment,” and “time × treatment interaction” 
will be used, followed when significant by the appropriate 
post hoc tests. Fisher’s exact test will be used to compare the 
frequencies of AEs, SAEs, related AEs, and related SAEs 
between the two treatment groups. For the primary endpoint, 
a P-value ,5% will be considered statistically significant. 
For all the other inferential analyses, P-values ,5% will be 
considered indicative only of potential differences between 
the two treatment groups.
Discussion
To our knowledge, the potential efficacy of metal trace 
elements against endometriosis-induced pelvic pain has 
never been tested in a double-blind, randomized, placebo-
controlled trial. Therefore, this is the main originality of 
this pilot study.
It was initially scheduled to identify and to recruit the 
patients on the sole basis of biopsy. However, it appeared that it 
could seriously prolong the inclusion period needed to achieve 
the requested sample size because in practice, some centers do 
not perform a biopsy and because in case of relapse (frequent 
for endometriosis), most of the time, a biopsy is not performed 
at all. Therefore, because of the chronicity of the disease and 
accuracy of laparoscopic/visual diagnosis of endometriosis, 
Table 3 Composition of Nutri Endo 1 and Nutri Endo 2
Ingredient Daily dose
Nutri Endo 1
Calcium 21.90 mg
Magnesium 4.37 mg
Zinc 0.80 mg
Manganese 0.11 mg
Potassium 0.07 mg
Sodium 0.02 mg
Copper 53.00 μg
Iron 0.26 μg
Nutri Endo 2
Calcium 22.94 mg
Magnesium 5.50 mg
Zinc 0.54 mg
Manganese 0.18 mg
Potassium 0.12 mg
Copper 52.00 μg
Iron 4.80 μg
Sodium 0.08 mg
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we confirmed the possibility to include a patient without recent 
histology. The diagnosis of endometriosis by visual inspection 
of the lesions will be based on the experience of the surgeon,23 
and this is a key factor to obtain a high correlation between 
macroscopic visual diagnosis and pathological diagnosis of 
a biopsy specimen. The visual appearance consistent with 
the diagnosis of endometriosis has a reported sensitivity of 
94%–97% and a specificity of 77%–85%, using histological 
diagnosis as a reference.24 This is the reason why we decided 
to reserve this type of eligibility only to patients attending 
recognized and trained endometriosis centers.25
For ethical reasons, it was not possible to let the patients 
without any golden standard treatments. Therefore, this is a 
particular challenge of this study to be able to show a supe-
riority of metal trace elements versus placebo in the context 
of an add-on therapy.
Instead of measuring pelvic pain at specific, fixed, and 
limited time points, we have decided to record it every day 
during the placebo run-in period and the 120-day treat-
ment phase and to compare the changes versus baseline in 
pain AUCs in the placebo and metal trace elements-treated 
groups. Together with the analysis of the QoL by means of 
the EHP-30 questionnaire, it will allow us to conclude to 
a potential positive effect of metal trace elements versus 
placebo on the QoL in endometriosis patients, which is 
at the end of the day the best and most important clinical 
objective to achieve in order to decrease the burden of 
endometriosis.
There is an important limitation to the study in terms of 
mechanistic approach. While, we were asked by the company 
Pronutri to evaluate its product in a strict double-blind, ran-
domized controlled study, as is the case for the majority of 
multicomponent drugs, plant extracts, food supplements, and 
homeopathic treatments, it will be impossible to know which 
trace element(s) is(are) responsible for an eventual positive 
effect in endometriosis-induced pelvic pain. At the opposite, 
if we fail to achieve the primary endpoint of the study, it 
will never be possible to improve these products. Therefore, 
this is a kind of all or none approach, which is frustrating 
for scientists, but we have to live with it. Ultimately, it is the 
QoL of our patients that is important and not the mechanism 
of action of a drug, whatever it is.
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